Condition: Waldenstrom Macroglobulinemia · Treatment Naive · Sponsor: Christian Buske
In Waldenström's macroglobulinemia (WM) chemotherapy induces only low CR/VGPR rates and response duration is limited. In addition, WM patients are often elderly, partly not tolerating chemotherapy related toxicities. Thus, innovative approaches are needed which combine excellent activity and tolerability in WM. Chemotherapy-free approaches are highly attractive for this patient group. Based on its high activity and favorable toxicity profile in indolent B-NHL such as CLL, Venetoclax was approved for the treatment of this diseases by the FDA and the European Medicines Agency (EMA). First data in relapsed/refractory WM have documented high activity and low toxicity of Venetoclax also in WM, including patients with prior Ibrutinib treatment or patients carrying CXCR4 mutations. Ibrutinib itself has high activity and a relatively low toxicity profile in WM, but has also major disadvantages: the main disadvantage is the need to apply this drug continuously. Furthermore, Ibrutinib efficacy depends largely on the genotype with a substantial drop in major responses and PFS in the presence of CXCR4 mutations and non-mutated MYD88. In particular the need of continuous treatment for Ibrutinib has prevented that Ibrutinib has become the standard of care outcompeting conventional Rituximab/chemotherapy. This is reflected in current guidelines such as the NCCN and the ESMO guidelines, which still see immunochemotherapy as a backbone of treatment, largely because of the advantage of a timel…
This description comes directly from the study's public registry record.
Dajana Kaszynski, MSc · +49 731 500 · studien.gla@uniklinik-ulm.de
Always discuss trial participation with your own doctor first.
| Onkologische Schwerpunktpraxis Bielefeld | Bielefeld, Germany | Recruiting |
| Klinikum Chemnitz gGmbH | Chemnitz, Germany | Recruiting |
| Klinikverbund Allgaeu gGmbH | Kempten, Germany | Recruiting |
| Universitaetsklinikum Schleswig-Holstein AöR | Kiel, Germany | Recruiting |
| Gemeinschaftsklinikum Mittelrhein gGmbH | Koblenz, Germany | Recruiting |
| Dr. Vehling-Kaiser MVZ GmbH | Landshut, Germany | Recruiting |
| Kliniken Maria Hilf GmbH Moenchengladbach | Mönchengladbach, Germany | Recruiting |
| Kliniken Ostalb, Standort Stauferklinikum Schwäbisch Gmünd | Mutlangen, Germany | Not Yet Recruiting |
| Haematologie und Onkologie Muenchen-Pasing MVZ GmbH | München, Germany | Recruiting |
| Universitaet Muenster | Münster, Germany | Recruiting |
| Christliches Klinikum Paderborn, Brüderkrankenhaus St. Josef Paderborn | Paderborn, Germany | Recruiting |
| Universitätsmedizin Rostock | Rostock, Germany | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05099471